Dyslipidemia in chronic kidney disease: managing a high-risk combination (Q35014627)

5 August 2017

1 reference

title

Dyslipidemia in chronic kidney disease: managing a high-risk combination (English)

1 reference

chronic renal insufficiency

5 August 2017

1 reference

1 reference

Veeraish Chauhan

1

1 reference

5 August 2017

Megha Vaid

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

5 August 2017

published in

Postgraduate Medicine

1 reference

5 August 2017

volume

121

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

54-61

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Nonreferral and nonacceptance to dialysis by primary care physicians and nephrologists in Canada and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

The inverse association between age and cholesterol level among older patients: the role of poor health status.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Hypertriglyceridemia as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Pleiotropic effects of statins: do they matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Statins and the acute-phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.11.2077

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.11.2077

1 reference

5 August 2017

1 reference